Malignant hyperthermia is a rare disorder that can occur in pat ients who are sensitive to certain agents used in genera l anesthesia. The treatment of malignant hyperthermia has not changed over the years, but prevention strategies have evolved. These strategies include an increase d emphasis on how patients are managed pri or to a surgical pro cedure, on the selection of the pa rticular anesthetic agent, and on postoperative vigilance. Susceptible patients who undergo simple excisions or a low degree of surgical stress can receive treatment safely in the offic e or ambulatory surgery center and be discharged the same day, p rovided that all known triggering agents are avoided. For more extensive procedures that cause a moderate level of surgical stress to susceptible patients, fac ilitiesfor managi ng malignant hyperthermia should be readily available. Susceptible patients who undergo high-stress invasive procedures should be hospitalized. Routine preoperative proph ylactic drug administration, even with dant rolene, is no longer considered necessaryfor any susceptibl e patients. All local anesthetics-including lidocaine, which had been p reviously contraindicated-are flO W considered to be safe for use in patients who are susceptible to malignant hyperthermia. In this article, we review the prevention, diagnosis, and management ofmalignant hyperthermia. We also report our expe rience in anesthetizing a patient who had a history of malignant hyperthermia-a case that illustrates the uncertainty that can complicate the management of such patients.
Introduction
Malignant hyperthermia is a rare disorder that can occur in patients who are sensitive to certain agents used in general anesthesia. Although malignan t hyperthermi a has been well describ ed in the literature, there continue to be conflicting recomm endati ons from different sources regarding its prevention. In this articl e, we review the past and current concepts pertinent to malignant hyperth ermia, with particular emphasis on otolaryngologic practice, especially in the outp atient setting. The recomm endations based on current data here are meant to serve onl y as a guide. Each surgeon must assess the circumstances of each individual patient in any given situation befo re proceeding on a cour se of action. As more is learned about malignant hyperthermia, guidelines for preoperative considerations and treatment can be expected to evolve. In addition to reviewing the prevention, diagno sis, and manage ment of malignant hypertherm ia, we also rep ort our experience in anesthetizing a pat ient who had a history of malignant hyperthermia-a case that illustrates the uncert ainty that can complicate the management of such patient s.
Case report
A 42-year-old man came to our center with a longstanding histor y of nasal obstruction. He had previously undergone surgery to repair a cleft lip and palate. Examination revealed the presence of a severe left septal deformity , bilat eral conch a bullo sas, and markedly enlarged turbinates. We initi ally decided to perform a septoplasty and a bilateral endosco pic resection of the concha bullo sas. However, durin g the patient ' s visit, he brought to our attention the fact that he had a history of an adverse reaction to anesthesia. Th ree dec ades earlier he had experienced a fever as high as 40°C, convulsions, and facial swe lling following the administrati on of general anesthesia durin g jaw surgery. He had not experienced any reaction to general anesthesia during two previous surgical manipul ations. An anesthesiology consult was obtained , and the patient was cleared for surgery at our ambulatory surgery center. Of note, no muscle biopsy was obtained .
On the morning of surgery, how ever, several issues were raised regardin g the patient' s safety. A que stion arose as to the wisdom of performing surgery on a patient with a probable history of malignant hyperthermia at an ambulatory surgery center that was not equipped with intensive care unit capabilities. Another issue conce rned the fact that anesthetic support was to be provid ed by a certified registered nurse anesthetist rather than an anesthesiologist. After much discussion and angst, we proceeded with the procedure as planned . No proph ylactic measures were taken other than to use known nontriggering anesthetic agents. The operation was completed with out incident, and the patient was discharged home later that day.
Discussion
Although malignant hyperthermia did not occur in our patient, this case illustrates the uncertainty that can complicate the management of patients who have a history of this disorder. Indeed , much controversy and confu sion attend to malignant hyperthermia and its diagnosis, its triggering factors, and its clinical manifestation s.
Although heat stroke as a postop erative complication has been described since 1900 ,1-3it was not until 1962 that Denbo rou gh et al'' first establi shed a link between malignant hyp erthermia and anesthesia and identified the familial pattern of this condition. Mortality was originally estimated to be nearly 80%, but since the introduction of the skeletal muscle relaxant dantr olene (the only specific drug indic ated for the treatment of malignant hyperth ermia) in 1975, mortality has been reported to be less than 10%. 5.6 Susceptibility and incidence. Susceptibility to malignant hyperthermia is known to be the result of abnormal calcium metabolism in the skeletal muscle fiber. It is also known to be an inherited autosomal-dominant condition of variable penetrance . However, the precise culprit has proved to be elusive, as genetic analysis has demon strated hetero geneity. Link age to the ryanodine receptor gene , the dihydropyridine membrane calcium channel , and the . second-mess enger inositol polyphosphate system has been found , but not consi stentl y.1,7 Link age to chromosome s I, 3, 5, 7, 17, and 19 has been discovered, but such genetic hetero geneity precludes a DNA-based diagnosis.I,2,5.6
The incidence of malignant hyperthermia is estim ated to be I in 15,000 children and I in 20,000 to 50,000 white adults. 1,5,8Fulminant malignant hyperthermic crises occ ur in 6.5% of all cases; the calculated incidence of these crises is 1 in 84,000 following the administration of volatile anesthetics and I in 62,000 following the administration of succinylcholine.1,8
The best way of determ inin g a patient ' s susceptibility to malignant hyperthermi a is the personal and family history , although an estimated 21 % of patients who experience malignant hyperthermia had unde rgone at least one previous uneventful anesthetic procedure (as had our patient)." Another much less practical mean s of identi fying susceptibility is the in vitro muscle contraction test, 434 which is the only objective means avai lable for identi fying a presympt omatic predisposition to malignant hyperthermia.v-? Only 10 centers in the United States perform this test (a list of these centers can be obtained by telephoning the Malign ant Hyperth ermia Association of the United States at [800] 986-4287 or by visiting its Web site at www.mhaus.org). A sample of the quadriceps femoris muscle is obtained by open biopsy and analyzed. I Th e patient must travel to a designated testing site because the test must be completed within 5 hours of the biop sy." Its reported sensitivity is 95 to 99% and its specificity is 78 to 93.6%.1 The only contraindications to this test are age less than 4 years and weight less than 20 kg.
Although it is not mandatory to obtain a biop sy for all patient s who have a history suggestive of malignant hyperthermia, all patients should be considered to be susceptible until proven otherwi se." Furthermore, given the autoso mal-dominant pattern of malignant hyperth ermia, any family history of this disorder automatically presumes susceptibility in all family members unless proven otherwise by the in vitro muscle con traction test.8.9
Again, it might be worthwhile to consult an anesthesiologist before operating on any patient with a possibl e susceptibility. A preoperative measurement of the patient ' s crea tine kinase (CK) level is not reco mmended.!?
Perioperative preventive measure s. In the past, patients with a histor y of malign ant hyperthermi a were treated with the utmo st caution preoperati vely as well as postoperati vely, regardl ess of whether any adverse event had occurred durin g anesthesia. Prophylactic medic ations were administered , and patient s were admitted for routine postope rati ve observation . Even routine office dental procedures were denied these patient s for fear that they would trigger an attack .'?
Tod ay, other pre-, intra-, and postoperative precautions are recommended for susceptible patients. IFor example, the anesthesia mach ine must be decont amin ated, especially any part of it that might have come into contact with a volatile anesthetic.The breathing circuit must be flush ed with fresh oxygen at a rate of 10 L/min for 10 minut es, and fres h soda-lime canisters should be installed. Sufficient amounts of dantrolene should be readily ava ilable, although curre nt opinion holds that premedic ation with dantrolene is obsolete. P ? Finally, of co urse, the patient must be appro priately monit ored.
Potent inhalation al anesthetics are know n triggers of malignant hyperthe rmia, and they should be avoided in susceptible patients (table) Amide local anesthetics, which include the commonly used agent lidocaine, were at one time contraindicated in susceptible patients because they can induce in vitro muscle contracture.t-" However, the doses needed to cause such contractures are extremely high. All local anesthetics are now considered to be safe in susceptible patients. In fact, in centers where the in vitro muscle contraction test is performed to test for malignant hyperthermia, physicians use the amide local anesthetic prilocaine.
Although there is no firm clinical evidence that catecholamines trigger malignant hyperthermia, the use of epinephrine remains controversial. Even though catecholamines are not flatly contraindicated, surgeons are urged to use caution.' It is believed that the sympathetic dysfunction seen in malignant hyperthermia might be a secondary phenomenon rather than a primary triggering event. Therefore, if epinephrine is deemed necessary, no more than 0.04 mg should be administered. 10 The act of waking a patient from anesthesia should be carried out in a relaxed and quiet atmosphere because stress might induce malignant hyperthermia, although the concept of stress as a trigger is controversial. t' Following minor surgery, an observation period of only 3 to 6 hours prior to discharge is appropriate; following major surgery, 24 hours in the intensi ve care unit is recommended. 8.9 In itself, a history of susceptibility to malignant hyperthermia does not warrant hospital admission following an uneventful surgery. 8 In 1992, Haas et al proposed three preventive guidelines for dentists who treat susceptible patients. 10 A similar set of recommendations for dermatologic surgeons was published by Murray et al in 1999. 5 With some modifications, both sets of guidelines can also be applied to otolaryngology practice:
• Nonstressful treatment (simple excisional surgery)
can be carried out in the clinic on an outpatient basis. • More extensive procedures that carry a moderate amount of stress can be carried out in an outpatient setting, provided that the surgeon has ready access to a facility that is equipped to manage malignant hyperthermia if need be. It might also be worthwhile to obtain an anesthesiology consult for risk assessment. • More invasive and more stressful procedures must be performed in a facility that has an active protocol for managing malignant hyperthermia. An anesthesiology consult might be required, and the procedure might have to be performed in an inpatient hospital setting that has intensive care capabilities.
Haas et al placed particular emphasis on the importance of stress factors that can induce malignant hyperthermia. 10 Factors such as the patient' s degree of apprehension , the length of the procedure, and the amount of trauma that is involved are key elements in assessing the risk of mal ignant hyperthermia in susceptible patients .
Signs and symptoms. When malignant hyperthermia
does occur, it is characterized by multiple nonspecific signs and laboratory values that evolve over time during and after exposure to anesthesia. These signs and symptoms are related to skelet al muscle hypermetabolism and ultimate breakdown. The onset of malignant hyperthermia can occur within 10 minutes or several hours following the administration of anesthesia.P The speed of onset is dependent on a combination of variable s, including the type of drug that triggered the attack , the concentration of the drug, and a patient' s unique calcium homeostasis physiologic vari ables .
Early signs and symptoms of malignant hyperthermia include masseter muscle rigidity (following succinylcholine administration), tachypnea, tachycardia, arrhythmias, a rising end-tidal carbon dioxide level , an increase in minute ventilation, and a hot soda-lime canister. Sub sequent sign s include cyanosis , cutaneous flushing , a rising core body temperature, hyperkalemi a, and acidemia.
The first manife station of malignant hyperthermia might be masseter spa sm, which is often more pronounced in children. The incidence of masseter spasm is I % following halothane and succinylcholine administration.I As a result , many anesthetists reserve succinylcholine for use during induction only under special circumstances in children." Several studi es have shown that as many as 50% of patients who experi enced masseter spasm were later found to be prone to malignant hyperthermia.l -v Moreover, an episode of trismus that lasts longer than 90 seconds and prevents laryngoscopy and intubation is clas sified as masseter muscle rigidity and must be regarded as pathologic.l -" The onset of masseter muscle rigidity is an indication to immediately discontinue anesthesia and admit the patient for overni ght observation for evidence of malignant hyperthermi a." Tran sient trismu s alone does not confirm malignant hyperthermia, but generalized rigidity is a definitive sign, and treatment should be initi ated promptly.
Late sign s are ominous. They include generaliz ed muscle rigidity, prolonged bleed ing, dark urine , oliguria, an increase in CK level, and myoglobinuria. In a fulminant crisis, the patient's core temperature can rise at a rate of 1 0 C every 5 minutes up to, and even above, 42 0 C; in rare cases , how ever, actual hyperthe rmia might be absent. 1. 8 Even with aggressive treatment, end-stage malignant hyperthermia can result in death . Therefore, prompt diagnosis and early treatment are important, but the diagno sis can be difficult in view of the nonspecific nature of some of its signs and symptoms and the exten sive differential diagno sis. The differential diagnosis includes, but is not 436 limited to, inadequ ate anesthesia or analgesia, an improper breathing circuit, sepsis, hypoxia, hypercapnia, iatrogenic hyperthermi a, heat stroke, the presence of radiologic contrast materi al in the central nervous system, anaphylaxis, pheochromocytoma, thyroid storm, cerebral ischemi a, neuroleptic malign ant syndrome, and other muscular diseases.v-" Several reviews have been published that provide more detail on the signs and symptoms of malignant hyperthermia.1.2.6.8.1I
Management. While preoperative con siderations have evolved over time , the mana gement of patients in the midst of a de veloping malignant hyperthermic crisis has not changed significantly over the year s. Malignant hyperthermia is treated on multiple front s. 1. 2.8 In addi tion to the immediate termination of a volatile anesthetic , other man agem ent step s include the commencement of mechanical ventil ation with 100% oxygen at a flow rate greater than 10 L/min, normalization of metabolic derangements, and a lowering of body temperature with topical ice or ice-water lavage. Dantrolene can also be started at the recommended dosage of 2.5 mg/kg administered intravenously every 5 minutes up to a total dose of 10 mg/kg until symptoms abate. In some circumstances, the total dose can be as high as 20 mg/kg.' Follo wing the stabilization of a hyperthermic crisi s, the patient must be admitted to the inten sive care unit for observation because malignant hyperthennia has been reported to recur in 25 % of patients ."
